EBMT 2021: Results of a study examining the use of CAR T therapy lisocabtagene maraleucel in both inpatients and outpatients.
Home / Resource Library / Liso-Cel Administration in Relapsed/Refractory LBCL Successful in Inpatient, Outpatient Settings at Nonuniversity Centers